Table 2 Results of the multivariate model analysis for progression-free survival.

From: KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab

Variable

HR (95% confidence interval)

p-value

Age

 > 65 years versus < 65 years

1.02 (0.40–2.60)

0.9

Gender

 Male versus Female

1.26 (0.48–3.08)

0.6

KRAS status

 Mutated versus wild-type

1.21 (0.40–2.60)

0.3

Number of metastatic sites

 > 2 versus 1–2

1.05 (0.41–2.70)

0.9

ECOG-PS

 2 versus 0–1

1.54 (0.61–3.76)

0.3

Treatment

 PC versus P

1.79 (0.80–3.72)

0.1

CNS metastasis

 Absent versus Present

0.67 (0.28–1.61)

0.3

KRAS4A isoform expression*

 High versus Low

0.31 (0.11–0.87)

0.02

PD-L1 expression*

 High versus Low

0.69 (0.25–1.84)

0.3

  1. *High and low expression of the the KRAS4A isoform and PD-L1 according to the Youden index (see text).
  2. HR hazard ratio, ECOG-PS, Eastern Cooperative Group Performance Status, P pembrolizumab, PC pembrolizumab/chemotherapy, CNS central nervous system.
Back to article page